The Usefulness of the Multiple Allergen Simultaneous Test-Chemiluminescent as Compared to the Phadia Immunocap IgE Test Panel System in Children and Adolescents
Ole D. Wolthers and Morten Staberg
Affiliation: Asthma and Allergy Clinic, Children’s Clinic Randers, Dytmaersken 9, DK-8900 Randers, Denmark.
Keywords: Allergy, allergic rhinitis, asthma, eczema, IgE, IgE tests, multiple allergen simultaneous test-chemiluminescent
assay, Phadia CAP test, IgE panel screening tests, rhinoconjunctivitis
Several patents of methods for diagnostic work-up of IgE-mediated disease have recently been acclaimed. The
aim of the present study was to assess the diagnostic usefulness of the Multiple allergen simultaneous testchemiluminescent
assay® (MAST CLA) as compared to the Phadia Immunocap® (Phadia CAP) allergen-specific IgE test
panel system. The design was a prospective, observational study in which MAST CLA and Phadia CAP test panels were
assessed in 105 children aged 1 to 17 years (46 girls and 59 boys) with a suspected diagnosis of rhinoconjunctivitis,
asthma, eczema or food allergy. The MAST CLA screening panel included 23 and 13, the Phadia CAP 10 inhalant and 6
food allergens. The MAST CLA screening panel found 353 sensitizations which were not detected by Phadia CAP, 93
(26.3%) of which were class 3 or 4 results. The sensitizations gave clinically useful information in 7 patients (6.6%). As
compared to the Phadia CAP the MAST CLA screening test panel adds little to the diagnostic work-up of IgE mediated
disease in children and adolescents.
Rights & PermissionsPrintExport